

Kidswell Bio (TYO: 4584)

The company's business progresses as planned at the beginning of the term, and the production of the master cell bank for SHED starts in accordance with GMP (good manufacturing practice)

◆ Financial results in 2Q of FY 3/2022: Sales increased 4 times year-on-year, and loss shrank

For 2Q of FY 3/2022, the company posted net sales of 740 million yen (up 324.5% year-on-year), an operating loss of 450 million yen (an operating loss of 682 million yen in the same period of the previous year), an ordinary loss of 463 million yen (an ordinary loss of 693 million yen in the same period of the previous year) and a net loss of 463 million yen (a net loss of 696 million yen in the same period of the previous year).

Filgrastim BS (GBS-001) and Darbepoetin alfa BS (GBS-011), which are the mainstay biosimilars (BS), performed well. In addition, sales of APIs related to the development of API manufacturing process for the 4th biosimilar product were recorded. On the other hand, the final development cost for the completion of the Master Cell Bank (MCB) for SHED in the regenerative medicine business was recorded in the cost of sales. Gross profit margin fell 14.3 pts. year-on-year. R&D expenses in SG&A included development investment for approval for Ranibizumab BS (GBS-007), whose posting was delayed from the previous term. Other SG&A expenses decreased by 27 million yen from the previous fiscal year due to continuous efforts to improve cost efficiency. As a result, deficit has narrowed from the same period of the previous year for all kinds of profits, including operating profit.

On the balance sheet, cash and deposits decreased by 486 million yen from the end of March 2021. On the other hand, work in process increased by 237 million yen, and total assets reached 3,859 million yen (3,933 million yen at the end of March 2021).

◆ Biosimilar business: The company obtained the approval for manufacturing and marketing of GBS-007

* **GBS-007:** The company has obtained the approval for the manufacturing and sales of the third product in the biosimilar business. Senju Pharmaceutical is a development partner for the biosimilar of ranibizumab, an anti-VEGF antibody drug for the treatment of AMD (age-related macular degeneration). It will be the first BS in the field of ophthalmology. The anti-VEGF antibody drug market in Japan alone is less than 100 billion yen in FY 2020. Of these, Lucentis (Novartis Pharma), which is considered to be a direct competitor, accounts for about 27 billion yen. Although it depends on the drug, some biosimilars take more than half the market share on a quantity basis after the launch. The details of the contract with Senju Pharmaceutical have not been disclosed, but the acquisition of manufacturing and sales approval is expected to contribute to profits from this term.

* **GBS-001, GBS-011:** For GBS-001 and GBS-011, which have already been launched by the business partners, the revenues from sale of APIs and royalties have been steadily increasing. The company is also taking continuous cost reduction measures to improve profitability.

* **Fourth biosimilar:** In addition to the above three items, the company is developing a fourth biosimilar. In 2Q, the sales of APIs related to the development of API manufacturing process were recorded, and in the medium-term strategic plan, the company aims to launch the product by FY 2025.

2Q update


Healthcare

As of Nov. 25, 2021

Share price (11/24)	¥511
52weeks high/low	¥864/393
ADVT (¥ mn, monthly)	¥76 mn
Mkt cap	¥16.0 bn
Shrs out.	31.434 mn, shrs
PER (22/3 CE)	-X
PBR (21/3 act)	8.67 X
ROE (21/3 act)	-68.5 %
Shr eqty ratio (21/9)	48.0 %

Listed market TSE Mothers

Stock price performance



%	1 mo.	3 mo.	12 mo.
Stock price	6.0%	-34.2%	-5.4%
Relative stock price	1.8%	-37.7%	1.4%

Points of interest

A drug discovery venture company originated from Hokkaido University. Leading biosimilar and delivered some products. Focuses on regenerative medicine applying SHED and development of new biopharmaceuticals. Aiming to return to profitability in FY2022/3 by expanding biosimilars.

This report (Company note) has been created at the request of Kidswell Bio. For details, refer to the disclaimer on the last page.

JPY, mn, %	Net sales	YoY %	Oper. profit	YoY %	Ord. profit	YoY %	Profit ATOP	YoY %	EPS (¥)
2018/3	1,059	-2.7	-913	-	-903	-	-904	-	-47.27
2019/3	1,021	-3.6	-805	-	-816	-	-856	-	-43.84
2020/3	1,077	-	-1,161	-	-1,187	-	-7,316	-	-264.65
2021/3	996	-7.5	-969	-	-991	-	-1,001	-	-34.79
2022/3 (CE)	1,900	90.7	-1,720	-	-1,740	-	-1,323	-	-58.18
2021/3 2Q	174	-44.4	-682	-	-693	-	-696	-	-24.49
2022/3 2Q	740	324.5	-450	-	-463	-	-463	-	-15.30



Progress of biosimilar business pipeline

Project	Therapeutic Area	Development Research	Clinical Trial		Application/Marketing/Approval/Launch	Partner
			Phase 1	Phase 3		
GBS-001 Filgrastim	Oncology	<div style="width: 100%; height: 10px; background-color: green;"></div>				Fuji Pharma Co., Ltd. Mochida Pharmaceutical Co., Ltd.
GBS-004 Bevacizumab	Oncology	<div style="width: 10%; height: 10px; background-color: green;"></div>				
GBS-005 Adalimumab	Immunological disease	<div style="width: 20%; height: 10px; background-color: green;"></div>				
GBS-007 Ranibizumab	Ophthalmic disease	<div style="width: 100%; height: 10px; background-color: green;"></div>			<div style="width: 10%; height: 10px; background-color: red;"></div>	Senju Pharmaceutical Co., Ltd. License out to Ocumension Therapeutics (China and Taiwan)
GBS-008 Palivizumab	Infectious disease	<div style="width: 15%; height: 10px; background-color: green;"></div>				
GBS-010 PEG-filgrastim	Oncology	<div style="width: 20%; height: 10px; background-color: green;"></div>				
GBS-011 Darbepoetin alfa	Renal disease	<div style="width: 100%; height: 10px; background-color: green;"></div>				Sanwa Kagaku Kenkyusho Co., Ltd.
GBS-012 Aflibercept	Ophthalmic disease	<div style="width: 5%; height: 10px; background-color: green;"></div>				Kishi Kasei Co., Ltd.


◇ Regenerative medicine (cell therapy) business: Creation of a master cell bank and start of joint research on designer cells

In the regenerative medicine business, which the company will focus on in the future, progress has been made in the SHED supply system and the designer cell field.

* **SHED**: In advancing the SHED business, it is essential to establish a stable raw materials supply system for research and development. The company has made upfront investments in building the system over the past few years as it entered this business field. The progress of the SHED business has accelerated significantly by the start of GMP production, which is oriented toward the creation of the master cell bank (MCB).

MCB accelerates regenerative medicine business (SHED)

■ SHED: Research & Development



13

Source: Company materials



The company named the manufacturing system S-Quatre SM (SHED Source Supply Service). The service is scheduled to be provided not only as a cell medicine, but also as a raw material for manufacturing clinical exosomes.

* **Designer Cell:** The company is also working on the development of "designer cells," which are enhanced cell therapies, in order to achieve high therapeutic goals. The company announced on September 8 that it has signed a joint research agreement with NanoCarrier Co., Ltd. By combining the gene delivery technology that utilizes nanomicelles possessed by nanocarriers with the company's SHED, the company will mainly develop an efficient method for introducing mRNAs into SHED, improve the therapeutic effect and disease site orientation with this method, and carry out joint research on the effectiveness of the gene transfer type designer SHED.

◇ Full-year outlook and progress of medium-term strategic plan

* **Full-year outlook for FY 3/2022:** At the interim announcement, the company retained its full-year guidance revealed at the beginning of the fiscal year. Sales achieved less than 40% of the full-year target, which assumes the income from GBS-007 during the remainder of the fiscal year. Excluding the one-off factors, gross profit is forecast to be 1 billion yen for the full year. One-time factors include sales and COGS resulting from the completion of the MCB and the drug substance sales and COGS related to the development of the drug substance manufacturing process for the 4th BS product.

* **Goal of moving into the black in FY 3/2023:** In the medium-term management plan, the company plans to make a profit in FY 3/2023. In FY 3/2023, GBS-007 will generate a full-year sales contribution, and milestone revenues look likely. As mentioned above, the company has already secured an underlying gross profit of 1 billion yen while the manufacturing and development costs of GBS-007 have peaked out. The company will keep R&D investments under control to accelerate licensing-out activities. With other SG&A expenses thoroughly controlled, the company aims to move into the black in FY 3/2023.

Financial data

FY (¥mn)	2020/3				2021/3				2022/3	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q
[Statements of income]										
Net sales	284	30	419	345	121	53	547	276	303	438
Cost of sales	77	8	359	209	5	35	46	34	122	154
Gross profit	207	22	60	136	116	19	500	242	182	283
SG&A expenses	417	423	381	365	354	463	465	565	491	425
R&D expenses	235	249	201	213	138	265	198	363	297	236
Operating loss	-210	-401	-321	-229	-238	-445	36	-323	-309	-142
Non-operating income	0	0	1	0	0	1	1	1	2	0
Non-operating expenses	2	1	20	4	7	5	4	8	6	8
Ordinary loss	-212	-402	-340	-233	-244	-450	33	-330	-314	-150
Extraordinary income	4	0	0	2						
Extraordinary expenses	5,939	0	0	194	0	1	8	0		
Loss before income taxes	-6,147	-402	-340	-425	-244	-451	26	-331	-314	-148
Total income taxes	1	0	3	-2	1	0	0	1	0	1
Net loss	-6,147	-403	-342	-424	-245	-451	25	-330	-314	-149
[Balance Sheets]										
Current assets	2,761	2,390	3,238	3,322	3,573	3,218	3,329	3,346	2,794	3,203
Cash equivalents and short-term securities	1,654	1,602	2,482	2,033	2,658	2,502	1,830	1,461	874	974
Non-current assets	330	427	418	270	379	393	340	588	728	656
Tangible assets	2	2	2	2	2	2	2	3	3	2
Investments and other assets	328	425	416	268	374	389	336	582	722	651
Total assets	3,091	2,817	3,656	3,592	3,952	3,611	3,670	3,934	3,522	3,859
Current liabilities	421	550	529	881	772	858	925	1,114	823	1,034
Short-term borrowings	25	25	25	25	25					
Non-current liabilities	25	24	1,224	1,224	1,384	1,287	1,231	1,209	1,051	826
Long-term debt			1,200	1,200	1,340	1,240	1,200	1,100	900	700
Long-term borrowing			600	600	600	600	600	600	600	600
Convertible bonds			600	600	740	640	600	500	300	100
Total liabilities	446	573	1,752	2,105	2,156	2,145	2,156	2,324	1,873	1,860
Total net assets	2,644	2,244	1,904	1,487	1,796	1,466	1,514	1,610	1,648	1,999
Total shareholders' equity	2,644	2,244	1,904	1,487	1,796	1,466	1,514	1,610	1,648	1,999
Capital stock	612	612	612	612	842	892	912	1,032	1,150	1,420
Legal capital reserve	9,917	9,917	9,917	9,917	10,147	10,197	10,217	10,338	10,456	10,725
Retained earnings	-7,908	-8,311	-8,653	-9,077	-9,322	-9,773	-9,748	-10,079	-10,393	-10,542
Stock acquisition right	38	43	51	57	70	82	101	116	134	145
Total liabilities and net assets	3,091	2,817	3,656	3,592	3,952	3,611	3,670	3,934	3,522	3,859
[Statements of cash flows]										
Cash flow from operating activities		-604		-1,325		-104		-1,267		-857
Loss before income taxes		-6,548		-7,314		-695		-999		-462
Cash flow from investing activities		-106		-137		-5		-22		-
Expenditure on acquisition of intangible fixed assets		-		-		-3		-3		-
Purchase of investment securities		-100		-100		-		-		-
Cash flow from financing activities		40		1,221		579		718		370
Income from the issuance of convertible bond-type bonds with stock acquisition rights		-		599		599		599		-
Income from issuance of shares by exercising stock acquisition rights		40		40		-		138		370
Income from issuance of stock acquisition rights		-		3		4		4		-
Net increase in cash and cash equiv.		-670		-240		468		-571		-486
Cash and cash equiv. at beginning of period		2,009		2,009		2,032		2,032		1,461
Cash and cash equiv. at end of period		1,602		2,032		2,501		1,461		974

Note) Regarding the cash flow statement, 2Q is the cumulative total of 1Q to 2Q, and 4Q is the cumulative total of 1Q to 4Q. Therefore, the beginning balance will also be the beginning balance in 1Q.

Source: Omega Investment from Company materials



General disclaimer and copyright

This report was created and displayed based on interviews with the company concerned and financial statements, but we do not guarantee the accuracy, completeness, or credibility of the content and data. This report is for informational purposes only and is not intended to solicit or recommend investment. Omega Investment is not responsible for the consequences of using this report.

This report is informed by the target company through interviews with the target company, but the hypotheses, conclusions and all other content contained in this report are based on research by Omega Investment.

Intellectual ownership, including copyrights of the text and data, belongs to Omega Investment. Distribution, transfer, reproduction, transfer or other use constitutes copyright infringement of this report and is strictly prohibited.